INSTRUCTIONS

Convention (a) AUSTRALIA

APPLICATION FOR A (b) STANDARD/PETTY PATENT

(a) If Convention application insert "Convention"

(b) Delete one

(c) MERRELL DOW PHARMACEUTICALS INC.

(d) 2110 East Galbraith Road
    Cincinnati, Ohio 45215
    United States of America

(e) hereby apply for the grant of a (a) Standard/Petty Patent for an invention entitled

(f) 4-SUBSTITUTED 17β-(CYCLOPROPYLAMINO)ANDROST-5-EN-3-OL
    AND RELATED COMPOUNDS USEFUL AS C 17-20 LYASE INHIBITORS

(g) which is described in the accompanying (g) complete specification.

(Note: The following applies only to Convention applications)

(h) Details of basic application(s)

<table>
<thead>
<tr>
<th>Application No.</th>
<th>Country</th>
<th>Filing Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>394,025</td>
<td>United States of America</td>
<td>August 15, 1989</td>
</tr>
</tbody>
</table>

(i) Address for Service: PHILLIPS ORMONDE AND FITZPATRICK

Patent and Trade Mark Attorneys

367 Collins Street
Melbourne, Australia 3000

(j) Dated (j) July 9, 1990

(k) MERRELL DOW PHARMACEUTICALS INC.

By

Gary B. Street
General Patent Counsel

1399 AU
AUSTRALIA

Patents Act

DECLARATION FOR A PATENT APPLICATION

In support of the (a) convention application made by (b) MERRELL DOW PHARMACEUTICALS INC.

(hereinafter called "applicant(s)" for a patent (c) for an invention entitled (d) 4-SUBSTITUTED 17β-(CYCLOPROPYLAMINO)ANDROST-5-EN-3-OL AND RELATED COMPOUNDS USEFUL AS C17-20 LYASE INHIBITORS

I/We (e) Gary D. Street, General Patent Counsel MERRELL DOW PHARMACEUTICALS INC.

2110 East Galbraith Road
Cincinnati, Ohio 45215, United States of America

do solemnly and sincerely declare as follows:
1. I am/We are the applicant(s).
2. I am/We are the actual inventor(s) of the invention and the facts upon which the applicant(s) is/are entitled to make the application are as follows:

(g) Applicant is the assignee of the above-entitled invention by virtue of a deed of Assignment from the actual inventors dated August 15, 1989

(Note: Paragraphs 3 and 4 apply only to Convention applications)

3. The basic application(s) for patent or similar protection on which the application is based is/are identified by country, filing date, and basic applicant(s) as follows:

(a) United States of America - August 15, 1989
By: Michael R. Angelastro and Thomas R. Blohm

4. The basic application(s) referred to in paragraph 3 hereof was/ware the first application(s) made in a Convention country in respect of the invention the subject of the application.

Declared at (b) Cincinnati, Ohio, U.S.A.
Date (l) July 9, 1990

(m)MERRELL DOW PHARMACEUTICALS INC.

By Gary D. Street
General Patent Counsel

To: The Commissioner of Patents

PHILLIPS ORMONDE & FITZPATRICK
Patent and Trademark Attorneys
367 Collins Street
Melbourne, Australia
The present invention is directed to 4-substituted \( \text{17\beta-(cyclopropylamino)androst-5-en-3\beta-ols} \) and related compounds and also to a method for using such compounds in the treatment of androgen-dependent disorders.

1. A compound of the formula

\[
\begin{align*}
\text{R} & \\
\text{N} & \\
\text{R'} &
\end{align*}
\]

wherein \( R \) is hydrogen or methyl; \( R' \) is hydrogen, \( C_1-C_4 \) alkyl.
or cyclopropyl; and Q is

\[\text{wherein } Z \text{ is } =O, \beta-\text{OH or } \beta-OZ' \text{ wherein } Z' \text{ is alkanoyl of 1-10 carbon atoms or substituted } C_{2-4} \text{ alkanoyl wherein the substituent is cyclopentane or benzene; } Y' \text{ is hydrogen or halogen; and } Y'' \text{ is methyl or halogen.}\]
AUSTRALIA
Patents Act

COMPLETE SPECIFICATION
(ORIGINAL)

Application Number:
Lodged:

Complete Specification Lodged:
Accepted:
Published:

Priority

Related Art:

Applicant(s):
Merrell Dow Pharmaceuticals Inc.
2110 East Galbraith Road, Cincinnati, Ohio, 45215, UNITED STATES OF AMERICA

Address for Service is:
PHILLIPS ORMONDE & FITZPATRICK
Patent and Trade Mark Attorneys
367 Collins Street
Melbourne 3000 AUSTRALIA

Complete Specification for the invention entitled:
4-SUBSTITUTED 17β-(CYCLOPROPYLAMINO)ANDROST-5-EN-3β-OL and RELATED COMPOUNDS USEFUL AS CYCLASE INHIBITORS

Our Ref: 183186
POF Code: 1432/1432

The following statement is a full description of this invention, including the best method of performing it known to applicant(s):

6006
4-SUBSTITUTED 17β-(CYCLOPROPYLAMINO)ANDROST-5-EN-3β-OL AND RELATED COMPOUNDS USEFUL AS C17-20 LYASE INHIBITORS

The present invention is directed to 4-substituted 17β-(cyclopropylamino)androst-5-en-3β-ols and related compounds and also to a method for using such compounds in the treatment of androgen-dependent disorders. More particularly, the present invention is directed to a group of compounds having the following general formula:

![Chemical Structure](image)

wherein R is hydrogen or methyl; R' is hydrogen, C1-C4 alkyl or cyclopropyl; and Q is

![Chemical Structure](image)

wherein Z is =O, β-OH or β-OZ' wherein Z' is alkanoyl of 1-10 carbon atoms or substituted C2-4 alkanoyl wherein the substituent is cyclopentane or benzene; Y' is hydrogen or substituted 1A

M01399
halogen; and \( Y'' \) is methyl or halogen. In the above structural formula, \( Z \) is shown as a divalent group and, in those definitions of \( Z \) which provide for only a single substituent (\( \beta \)), the second valence is occupied by hydrogen. Examples of the alkanoyl groups containing 1-10 carbon atoms are acetyl, propionyl, butanoyl, and decanoyl; examples of the substituted \( C_{2-4} \) alkanoyl groups are cyclopentanepropionyl and benzenepropionyl. The halogen atoms referred to above can be fluorine, chlorine or bromine. Preferred compounds are those in which \( Q \) has structure I and, more particularly, those compounds in which \( Q \) has structure I and \( Y' \) and \( Y'' \) are both halogen. A still further preferred group of compounds are those wherein \( Q \) has structure I and \( Y' \) and \( Y'' \) are both fluorine.

Acid addition salts of the aforesaid compounds with pharmaceutically acceptable acids are equivalent to the above amines for the purposes of this invention. Illustrative of such salts are the salts with inorganic acids such as, for example, hydrochloric, hydrobromic, sulfuric, phosphoric and like acids; with organic carboxylic acids such as, for examples, acetic, propionic, glycolic, lactic, pyruvic, malonic, succinic, fumaric, malic, tartaric, citric, ascorbic, maleic, hydroxymaleic and dihydroxymaleic, benzoic, phenylactic, 4-aminobenzoic, 4-hydroxybenzoic, anthranilic, cinnamic, salicylic, 4-aminosalicylic, 2-phenoxybenzoic, 2-acetoxybenzoic, mandelic and like acids; and with organic sulfonic acids such as methanesulfonic acid and \( p \)-toluenesulfonic acids.

Examples of specific compounds within the scope of the present invention are the following:

17\( \beta \)-(Cyclopropylamino)-4,4-difluoroandrost-5-en-3\( \beta \)-ol.

4,4-Difluoro-17\( \beta \)-(1-methylcyclopropylamino)androst-5-en-3\( \beta \)-ol.

3\( \beta \)-Acetoxy-17\( \beta \)-(cyclopropylamino)-4,4-difluoroandrost-5-ene.
The compounds of the present invention are conveniently prepared by the reduction of an appropriate steroidal imine or enamine, wherein the compound used is a 3-hydroxy or 3-alkanoylhydroxy-Δ^3-steroid, with a hydride reducing agent. Where the starting material is an imine, the reaction can be illustrated as follows:

In this case, the reduction is carried out using a hydride reducing agent, preferably sodium borohydride, in an alkanol solvent. To obtain the compounds which contain an esterified 3-hydroxy group, the amine as shown above is reacted with carbobenzoxy chloride to give the corresponding N-carbobenzoxy compound. This is then acylated using, for example, acetic anhydride to give the corresponding 3-acetoxy steroid. The N-carbobenzoxy protecting group is then removed by treatment with hydrogen bromide and acetic acid or by catalytic transfer hydrogenation. Alternatively, the 3-acetoxy group, or some other protected oxygen group such as a 3-(2-tetrahydroxypropyloxy) group can be present on
the steroid nucleus before the 17-imino group is introduced. In all cases, the product obtained is a secondary amine which can be converted to the corresponding N-methyl compound by treatment with formaldehyde and formic acid in an Eschweiler-Clarke reaction or by reaction with aqueous formaldehyde and sodium borohydride. Where the 3-hydroxy group is present in the form of an ester of a tetrahydropyran ether, these groups can be removed by standard procedures. That is, the ester group can be removed by base hydrolysis or the ether can be removed by treatment with dilute acid.

Those compounds wherein R' is C2-4 alkyl can be obtained from a 17-cyclopropylamino steroid. This is reacted, for example, with acetyl chloride to give the corresponding acetamide which is then reduced with sodium cyanoborohydride to give the N-ethyl compound. In those cases where the above reaction with acetyl chloride also gives the 3-ester, the ester group can be removed, after the reduction, by base hydrolysis such as a combination of potassium carbonate, methanol and tetrahydrofuran or by acid hydrolysis such as with hydrochloric acid. In the latter case, the hydrochloride salt is obtained.

The 3-hydroxy-Δ5-compound obtained above can optionally be converted to the corresponding 3-keto-Δ5-compound by an Oppenauer oxidation using aluminum isopropoxide.

The imine starting material used in this process can be obtained by the reaction of an appropriate 4-substituted 3-oxygenated androst-5-en-17-one with the appropriate cyclopropylamine in refluxing methanol. The reaction is carried out in the presence of a dehydrating agent to remove water from the reaction mixture as it is formed. The term "3-oxygenated" used with regard to the starting material means that it can contain a free hydroxy group at the 3-position or the 3-hydroxy group can be present in the form of an ester with an alkanoic acid containing up to 6 carbon atoms.
or the 3-hydroxy group can be in the form of a protected alcohol group such as a tetrahydropyranoyloxy group.

The 17-ketone referred to in the preceding paragraph can be obtained from the corresponding alcohol by oxidation with pyridinium chlorochromate in methylene chloride. Specifically, oxidation of 4,4-difluoro-3β-(2-tetrahydropyranoyloxy)androst-5-en-17β-ol in this way gives 4,4-difluoro-3β-(2-tetrahydropyranoyloxy)androst-5-en-17-one. To obtain the 4,4-difluoro-3β-(2-tetrahydropyranoyloxy)androst-5-en-17β-ol, 4,4-difluoro-17β-hydroxyandrost-3-one is reacted with acetyl chloride in methylene chloride in the presence of triethylamine to give the corresponding 17-acetate ester which is then reduced using sodium borohydride in ethanol to give the corresponding 3β-hydroxy compound. This 3β-hydroxy compound is then reacted with dihydropyran and hydrogen chloride in methylene chloride to give the corresponding 3-(2-tetrahydropyranoyloxy) compound which is then hydrolyzed using lithium hydroxide in a mixture of dioxane and water to give the desired 4,4-difluoro-3β-(2-tetrahydropyranoyloxy)androst-5-en-17β-ol. Similar procedures can be used to obtain compounds having only one methyl or halogen substituent at the 4-position.

When the reduction referred to initially is carried out on an enamine, borane or a borohydride reducing agent such as sodium borohydride is used as the reducing agent. The necessary enamine starting material is obtained by the condensation of dehydroepiandrosterone with an appropriate secondary amine such as dicyclopropylamine. The alcohol final product obtained in this process can be acylated with an appropriate anhydride, such as acetic anhydride, to give the corresponding 3-acetoxy compound or it can be oxidized in an Oppenauer oxidation to give the corresponding 3-keto-Δ5-compound.

The present compounds are useful as inhibitors of steroid C_{17-20} lyase. The steroid C_{17-20} lyase enzyme cata-
lyzes the conversion of the C21 steroids pregnenolone and progesterone to the C19 steroids dehydroepiandrosterone and androstenedione, which are the precursors of the androgens, testosterone and 5α-dihydrotestosterone. Androstenedione and testosterone, in turn, are the precursors of the estrogens, estrone and estradiol. Thus, inhibition of C17-20 lyase by the present compounds can reduce formation of the estrogens as well as the androgens. Consequently, the present compounds are useful for treating various androgen-dependent disorders. The present invention thus also encompasses a method for treating androgen-dependent disorders which comprises administering to an individual suffering from such a disorder an effective amount of a compound of the present invention. More particularly, the present compounds are useful in the treatment of prostatic carcinoma, benign prostatic hyperplasia, male-pattern baldness and virilism and hirsutism (in women). The compounds of the present invention are also useful in the treatment of estrogen-dependent diseases, such as estrogen-dependent breast cancer.

It is well established that reduction of serum testosterone levels is useful in the treatment of many cases of prostatic carcinoma. In clinical practice, this has been accomplished by orchietomy or by diethylstilbestrol treatment but the first approach is often psychologically unacceptable while a number of side effects are associated with the second approach. Thus, an alternative approach to testosterone reduction is desirable and this can be accomplished by the administration of the present compounds. To the extent that prostatic carcinoma is androgen-dependent, the present compounds would block the source of androgens and thus serve as an appropriate treatment for this condition.

The activity of the present compounds as inhibitors of steroid C17-20 lyase is established using microsomal preparations of the steroid C17-20 lyase enzyme from human or
laboratory animal testes; human testes used for this purpose are obtained from therapeutic orchiectomies. The enzyme is incubated with NADPH and the test compound in the concentration range $5 \times 10^{-8} M$ to $3 \times 10^{-6} M$ and the extent of inhibition of the enzyme is determined with time-dependency of inhibition being established by a decline in enzyme activity with the time of exposure to the test compound. Time-dependency of inhibition often implies irreversible inactivation of the enzyme and irreversibility is specifically established by inability to restore enzyme activity by dialysis under conditions which maintained activity of native enzyme.

In the treatment of the various androgen-dependent disorders described earlier, the compounds of the present invention may be administered orally to the patient being treated to achieve the particular effect desired. The amount of compound to be administered will vary over a wide range and can be any effective amount. Depending on the patient to be treated, and the severity of the condition being treated, the effective amount of compound administered will vary from about 0.625 to 62.5 mg/kg of body weight per day and preferably from 5 to 30 mg/kg of body weight per day. Unit dosages for oral administration may contain, for example, from 25 to 500 mg of a compound of the invention. Alternatively, the present compounds can be administered by parenteral routes or by implants.

In practicing the method of this invention, the active ingredient is preferably incorporated in a composition containing a pharmaceutical carrier and from about 5 to about 90% by weight of the cyclopropylamino steroid or a pharmaceutically-acceptable salt thereof. The term "pharmaceutical carrier" refers to known pharmaceuticals excipients useful in formulating pharmaceutically active compounds for internal administration to animals, and which are substantially non-toxic and non-sensitizing under conditions of use. The compositions can be prepared by known
techniques for the preparation of tablets or capsules and can contain suitable excipients known to be useful in the preparation of the particular type of composition desired. Suitable pharmaceutical carriers in formulation techniques are found in standard texts, such as *Remington's Pharmaceutical Sciences*, Mack Publishing Company, Easton, Pennsylvania.

The following examples are presented to illustrate the present invention but they should not be construed as limiting it in any way.

**EXAMPLE 1**

To a solution of 21 g of 4,4-difluoro-3β-(2-tetrahydro-pyranyloxy)androst-5-en-17-one in a mixture of 175 ml of cyclopropylamine and 150 ml of methanol there is added 5 g of molecular sieves. The reaction mixture is refluxed for 48 hours, cooled to room temperature, and filtered through magnesium sulfate. The magnesium sulfate is washed with ethyl acetate and the solvent is removed from the combined filtrates under reduced pressure to give 17-(cyclopropylimino)-4,4-difluoro-3β-(2-tetrahydro-pyranyloxy)androst-5-ene.

**EXAMPLE 2**

To a solution of 9.1 g of 17-(cyclopropylimino)-4,4-difluoro-3β-(2-tetrahydro-pyranyloxy)androst-5-ene in 200 ml of dry ethanol is added 2 g of sodium borohydride. The reaction mixture is stirred at room temperature for 3 hours and then 100 ml of solvent is removed from the mixture under reduced pressure. The reaction mixture is then quenched with dilute acetic acid, diluted with 600 ml of water, and the pH is adjusted to 14 by the addition of sodium hydroxide. The aqueous mixture is extracted 3 times with 600 ml potions of ethyl acetate and the combined organic extracts are dried over magnesium sulfate. Removal of the solvent under reduced pressure gives the desired 17β-(cyclopropylamino)-4,4-difluoro-3β-(2-tetrahydro-pyranyloxy)androst-5-ene as a white solid. This material is treated with a catalytic...
amount of hydrochloric acid in dioxane to remove the tetrahydropyranyl protecting group. This compound has the following structural formula:

\[
\begin{array}{c}
\text{NH} \\
\text{HO} \\
\text{F} \\
\text{F}
\end{array}
\]

**EXAMPLE 3**

Reaction of 4,4-difluoro-3β-(2-tetrahydropyranyloxy)-androst-5-en-17-one with 1-methylcyclopropylamine according to the procedure described in Example 1 gives 4,4-difluoro-17-(1-methylcyclopropylimino)-3β-(2-tetrahydropyranyloxy)-androst-5-en-3β-ol. This is then reduced with sodium borohydride and the tetrahydropyranyl group is removed according to the procedure described in Example 2 to give 4,4-difluoro-17β-(1-methylcyclopropylamino)androst-5-en-3β-ol.

**EXAMPLE 4**

Reaction of 17-(cyclopropylimino)-4,4-difluoro-3-(2-tetrahydropyranyloxy)androst-5-en-3β-ol with an excess of acetic anhydride in the presence of a base (pyridine) followed by removal of the excess anhydride and acetic acid gives 3β-acetoxy-17-(cyclopropylimino)-4,4-difluoro-3-(2-tetrahydropyranyloxy)androst-5-ene. Reduction of this ester with sodium borohydride and removal of the tetrahydropyranyl group according to the procedure described in Example 2 gives 3β-acetoxy-17β-(cyclopropylamino)-4,4-difluoroandrost-5-ene. 3β-(Cyclopentanepropionyloxy)-17β-(cyclopropylamino)-4,4-difluoroandrost-5-ene and 3β-(benzenepropionyloxy)-17β-
(cyclopropylamino)-4,4-difluoroandrosten-5-ene are obtained in a similar way using the appropriate acid chlorides.

**EXAMPLE 5**

To a mixture of 10 ml of formic acid and 5 ml of formaldehyde is added 1.4 g of 17β-(cyclopropylamino)-4,4-difluoroandrosten-5-en-3β-ol. The mixture is heated at reflux for 5 hours, the volume is then reduced to 7.5 ml in vacuo, and 10 ml of 50% (w/w) aqueous sodium hydroxide is added. The aqueous layer is separated and extracted with ethyl acetate and the combined organic solutions are dried over magnesium sulfate. The solvent is then removed in vacuo and the residual product is purified by flash chromatography to give 4,4-difluoro-17β-[N-methyl(cyclopropylamino)]androsten-5-en-3β-ol.

**EXAMPLE 6**

A solution of 1.5 grams of 17β-(cyclopropylamino)-4,4-difluoroandrosten-5-en-3β-ol in 80 ml of toluene is concentrated to 75% of its original volume and 20 ml of cyclohexanone is added. The mixture is again concentrated to 75% of its volume and 1.5 g of aluminum isopropoxide is added. The reaction mixture is refluxed for 45 minutes, cooled to room temperature, and 50 ml of water and 5 ml of concentrated hydrochloric acid are added. The solution is then treated with 11 g of sodium hydroxide and the two phases are separated. The aqueous phase is extracted with 50 ml of ethyl acetate and the combined organic extracts are dried over sodium sulfate. The solvent is removed in vacuo and crystallization of the residue from hexane/ethyl acetate gives 17β-(cyclopropylamino)-4,4-difluoroandrosten-5-en-3-one.
The claims defining the invention are as follows:

1. A compound of the formula

\[ R' - N - R'' \]

wherein \( R \) is hydrogen or methyl; \( R' \) is hydrogen, \( C_1-C_4 \) alkyl or cyclopropyl; and \( Q \) is

\[ R' \]

wherein \( Z \) is \( \beta-OH \) or \( \beta-OZ' \) wherein \( Z' \) is alkanoyl of 1-10 carbon atoms or substituted \( C_2-C_4 \) alkanoyl wherein the substituent is cyclopentane or benzene; \( Y' \) is hydrogen or halogen; and \( Y'' \) is methyl or halogen.

2. A compound according to Claim 1 which has the formula:

\[ \text{M01399} \]

-ll-
wherein \( Z \) is =O, \( \beta \)-OH or \( \beta \)-OZ' wherein \( Z' \) is alkanoyl of 1-10 carbon atoms or substituted \( C_2-4 \) alkanoyl wherein the substituent is cyclopentane or benzene; \( R \) is hydrogen or methyl; \( R' \) is hydrogenn or \( C_1-C_4 \) alkyl; \( Y' \) is halogen; and \( Y'' \) is methyl or halogen.

3. A compound according to Claim 1 which has the formula:

wherein \( Z \) is =O, \( \beta \)-OH or \( \beta \)-OZ' wherein \( Z' \) is alkanoyl of 1-10 carbon atoms or substituted \( C_2-4 \) alkanoyl wherein the substituent is cyclopentane or benzene; \( R \) is hydrogen or methyl; \( R' \) is hydrogenn or \( C_1-C_4 \) alkyl.
4. A compound according to Claim 1 which is 17β-(cyclopropylamino)-4,4-difluoroandrost-5-en-3β-ol.

5. A compound according to Claim 1 which is 17β-(cyclopropylamino)-4,4-difluoroandrost-4-en-3-one.

6. A method for treating androgen-dependent disorders which comprises administering to an individual suffering from such a disorder an effective amount of a compound of the formula

\[
\begin{align*}
\text{R} & \quad \text{N-R'} \\
\text{Q} & \\
\end{align*}
\]

wherein R is hydrogen or methyl; R' is hydrogen, C1-C4 alkyl or cyclopropyl; and Q is

[Diagram]

wherein Z is =O, β-OH or β-OZ' wherein Z' is alkanoyl of 1-10 carbon atoms or substituted C2-4 alkanoyl wherein the substituent is cyclopentane or benzene; Y' is hydrogen or halogen; and Y" is methyl or halogen.

7. A method according to Claim 6 for treating androgen-dependent disorders which comprises administering to an individual suffering from such a disorder an effective amount of a compound of the formula:
wherein Z is =O, β-OH or β-OZ' wherein Z' is alkanoyl of 1-10 carbon atoms or substituted C₂₋₄ alkanoyl wherein the substituent is cyclopentane or benzene; R is hydrogen or methyl; R' is hydrogen or C₁₋₄ alkyl; Y' is halogen; and Y" is methyl or halogen.

8. A method according to Claim 6 which comprises administering an effective amount of 17β-(cyclopropylamino)-4,4-difluoroandrost-5-en-3β-ol.

9. A process for the preparation of a compound of the formula:
wherein $Y'$ is halogen and $Y''$ is methyl or halogen, which comprises reducing a compound of the formula

with a hydride reducing agent in an alkanol solvent.

10. A compound as claimed in Claim 1 substantially as hereinbefore defined with reference to any one of the examples.

11. A method as claimed in Claim 6 substantially as hereinbefore described with reference to any one of the examples.

12. A process as claimed in Claim 9 substantially as hereinbefore described with reference to any one of the examples.

Dated: 6 August 1990
PHILLIPS ORMONDE & FITZPATRICK
Attorneys for: MERRELL DOW PHARMACEUTICALS INC.

KC